Apoptosis of osteosarcoma cultures by the combination of the cyclin-dependent kinase inhibitor SCH727965 and a heat shock protein 90 inhibitor

Cell Death and Disease

Volumn 4, Issue 3, 2013, Pages

  Fu, W ^a   Sharma, S S ^a   Ma, L ^a   Chu, B ^a   Bui, M M ^b   Reed, D ^b   Pledger, W J ^a,b  

^a Sarcoma Division   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Apoptosis; Cyclin Dependent Kinase; Heat Shock Protein 90; Nvp Auy922; Osteosarcoma; Sch727965

Indexed keywords

5 (2,4 DIHYDROXY 5 ISOPROPYLPHENYL) 4 (4 MORPHOLINOMETHYLPHENYL) 3 ISOXAZOLECARBOXYLIC ACID ETHYLAMIDE; ALKALINE PHOSPHATASE; ALVESPIMYCIN; ANTINEOPLASTIC AGENT; DINACICLIB; HEAT SHOCK PROTEIN 90 INHIBITOR; NVP HSP 990; OSTEOCALCIN; OSTEOPONTIN; PROTEIN BAX; TANESPIMYCIN; UNCLASSIFIED DRUG; 5-(2,4-DIHYDROXY-5-ISOPROPYLPHENYL)-4-(4-MORPHOLIN-4-YLMETHYLPHENYL)ISOXAZOLE-3-CARBOXYLIC ACID ETHYLAMIDE; BAX PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE; FUSED HETEROCYCLIC RINGS; HEAT SHOCK PROTEIN 90; ISOXAZOLE DERIVATIVE; LUMINESPIB; PROTEIN KINASE INHIBITOR; PYRIDINIUM DERIVATIVE; RESORCINOL DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE ARREST; CONTROLLED STUDY; CYTOSOL; DRUG EFFICACY; DRUG EXPOSURE; DRUG POTENTIATION; FETUS; FIBROBLAST; HUMAN; HUMAN CELL; MITOCHONDRION; OSTEOBLAST; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; BONE TUMOR; CELL CYCLE; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BICYCLO COMPOUNDS, HETEROCYCLIC; BONE NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASES; CYTOSOL; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HSP90 HEAT-SHOCK PROTEINS; HUMANS; ISOXAZOLES; MITOCHONDRIA; OSTEOSARCOMA; PROTEIN KINASE INHIBITORS; PROTEIN TRANSPORT; PYRIDINIUM COMPOUNDS; RESORCINOLS; SIGNAL TRANSDUCTION;

EID: 84875888282     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.101     Document Type: Article

References (50)

1. Sakamoto A, Iwamoto Y. Current status and perspectives regarding the treatment of osteosarcoma: chemotherapy. Rev Recent Clin Trials 2008; 3: 228-231.
2. Allison DC, Carney SC, Ahlmann ER, Hendifar A, Chawla S, Fedenko A et al. A meta-analysis of osteosarcoma outcomes in the modern medical era. Sarcoma 2012; 2012: 704872.
3. Tan ML, Choong PF, Dass CR. Osteosarcoma: conventional treatment versus gene therapy. Cancer Biol Ther 2009; 8: 106-117.
4. Fu W, Ma L, Wang X, Bui MM, Gemmer J, Altiok S et al. The cyclin-dependent kinase inhibitor SCH727965 (dinaciclib) induces the apoptosis of osteosarcoma cells. Mol Cancer Ther 2011; 10: 1018-1027.
5. Parry D, Guzi T, Shanahan F, Davis N, Prabhavalkar D, Wiswell D et al. Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol Cancer Ther 2010; 9: 2344-2353.
6. Contreras-Vallejos E, Utreras E, Gonzalez-Billault C. Going out of the brain: non-nervous system physiological and pathological functions of Cdk5. Cell Signal 2012; 24: 44-52.
7. Taipale M, Jarosz DF, Lindquist S. HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol 2010; 11: 515-528.
8. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005; 5: 761-772.
9. Picard D. A stress protein interface of innate immunity. EMBO Rep 2008; 9: 1193-1195.
10. Maloney A, Clarke PA, Workman P. Genes and proteins governing the cellular sensitivity to HSP90 inhibitors: a mechanistic perspective. Curr Cancer Drug Targets 2003; 3: 331-341.
11. Schnur RC, Corman ML, Gallaschun RJ, Cooper BA, Dee MF, Doty JL et al. Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives. J Med Chem 1995; 38: 3806-3812.
12. Egorin MJ, Lagattuta TF, Hamburger DR, Covey JM, White KD, Musser SM et al. Pharmacokinetics, tissue distribution, and metabolism of (dimethylaminoethylamino)- 17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats. Cancer Chemother Pharmacol 2002; 49: 7-19.
13. Khong T, Spencer A. Targeting HSP 90 induces apoptosis and inhibits critical survival and proliferation pathways in multiple myeloma. Mol Cancer Ther 2011; 10: 1909-1917.
14. Brough PA, Aherne W, Barril X, Borgognoni J, Boxall K, Cansfield JE et al. 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. J Med Chem 2008; 51: 196-218.
15. Kamal A, Thao L, Sensintaffar J, Zhang L, BoehmMF, Fritz LC et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003; 425: 407-410.
16. Holzbeierlein JM, Windsperger A, Vielhauer G. Hsp90: a drug targetCurr Oncol Rep 2010; 12: 95-101.
17. Porter JR, Fritz CC, Depew KM. Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy. Curr Opin Chem Biol 2010; 14: 412-420.
18. Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, Henson PM. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol 1992; 148: 2207-2216.
19. Zong W, Thompson CB. Necrotic death as a cell fate. Genes Dev 2006; 20: 1-15.
20. Chang HY, Yang X. Proteases for cell suicide: functions and regulation of caspases. Microbiol Mol Biol Rev 2000; 64: 821-846.
21. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007; 26: 1324-1337.
22. Meijer L, Borgne A, Mulner O, Chong JP, Blow JJ, Inagaki N et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 1997; 243: 527-536.
23. Wang D, de la Fuente C, Deng L, Wang L, Zilberman I, Eadie C et al. Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors. J Virol 2001; 75: 7266-7279.
24. Chao SH, Fujinaga K, Marion JE, Taube R, Sausville EA, Senderowicz AM et al. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J Biol Chem 2000; 275: 28345-28348.
25. Senderowicz AM, Sausville EA. Preclinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst 2000; 92: 376-387.
26. Toogood PL, Harvey PJ, Repine JT, Sheehan DJ, VanderWel SN, Zhou H et al. Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. J Med Chem 2005; 48: 2388-2406.
27. Stepanova L, Leng X, Parker SB, Harper JW. Mammalian p50Cdc37 is a protein kinase targeting subunit of Hsp90 that binds and stabilizes Cdk4. Genes Dev 1996; 10: 1491-1502.
28. Srethapakdi M, Liu F, Tavorath R, Rosen N. Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest. Cancer Res 2000; 60: 3940-3946.
29. Basso AD, Solit DB, Munster PN, Rosen N. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene 2002; 21: 1159-1166.
30. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998; 273: 5858-5868.
31. Gillet JP, Calcagno AM, Varma S, Davidson B, Bunkholt Elstrand M, Ganapathi R et al. Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma. Clin Cancer Res 2012; 18: 3197-3206.
32. Menezes DL, Taverna P, Jensen MR, Abrams T, Stuart D, Yu GK et al. The novel oral Hsp90 inhibitor NVP-HSP990 exhibits potent and broad-spectrum antitumor activities in vitro and in vivo. Mol Cancer Ther 2012; 11: 730-739.
33. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009; 136: 823-837.
34. Powers MV, Jones K, Barillari C, Westwood I, van Montfort RL, Workman P. Targeting HSP70: the second potentially druggable heat shock protein and molecular chaperoneCell Cycle 2010; 9: 1542-1550.
35. Powers MV, Clarke PA, Workman P. Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. Cancer Cell 2008; 14: 250-262.
36. Bagatell R, Paine-Murrieta GD, Taylor CW, Pulcini EJ, Akinaga S, Benjamin IJ et al. Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents. Clin Cancer Res 2000; 6: 3312-3318.
37. Munster PN, Basso A, Solit D, Norton L, Rosen N. Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB and schedule-dependent manner. Clin Cancer Res 2001; 7: 2228-2236.
38. Vogel S, Raulf N, Bregenhorn S, Biniossek ML, Maurer U, Czabotar P et al. Cytosolic Bax: does it require binding proteins to keep its pro-apoptotic activity in checkJ Biol Chem 2012; 287: 9112-9127.
39. Whittaker SR, Te Poele RH, Chan F, Linardopoulos S, Walton MI, Garrett MD et al. The cyclin-dependent kinase inhibitor seliciclib (R-roscovitine; CYC202) decreases the expression of mitotic control genes and prevents entry into mitosis. Cell Cycle 2007; 6: 3114-3131.
40. Zhang T, Jiang T, Zhang F, Li C, Zhou YA, Zhu YF et al. Involvement of p21Waf1/Cip1 cleavage during roscovitine-induced apoptosis in non-small cell lung cancer cells. Oncol Rep 2010; 23: 239-245.
41. Jorda R, Havlicek L, McNae IW, Walkinshaw MD, Voller J, Sturc A et al. Pyrazolo [4,3-d]pyrimidine bioisostere of roscovitine: evaluation of a novel selective inhibitor of cyclin-dependent kinases with antiproliferative activity. J Med Chem 2011; 54: 2980-2993.
42. Schutte B, Nieland L, van Engeland M, Henfling ME, Meijer L, Ramaekers FC. The effect of the cyclin-dependent kinase inhibitor olomucine on cell cycle kinetics. Exp Cell Res 1997; 236: 4-15.
43. Wesierska-Gadek J, Borza A, Komina O, Maurer M. Impact of roscovitine, a selective CDK inhibitor, on cancer cells: bi-functionality increases its therapeutic potential. Acta Biochim Pol 2009; 56: 495-501.
44. Okamoto J, Mikami I, Tominaga Y, Kuchenbecker KM, Lin YC, Bravo DT et al. Inhibition of Hsp90 leads to cell cycle arrest and apoptosis in human malignant pleural mesothelioma. J Thorac Oncol 2008; 3: 1089-1095.
45. Garcia-Morales P, Carrasco-Garcia E, Ruiz-Rico P, Martinez-Mira R, Menendez-Gutierrez MP, Ferragut JA et al. Inhibition of Hsp90 function by ansamycins causes downregulation of cdc2 and cdc25c and G2/M arrest in glioblastoma cell lines. Oncogene 2007; 26: 7185-7193.
46. Hostein I, Robertson D, DiStefano F, Workman P, Clarke PA. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17- demethoxygeldanamycin results in cytostasis and apoptosis. Can Res 2001; 61: 4003-4009.
47. Lesko E, Gozdzik J, Kijowski J, Jenner B, Wiecha O, Majka M. HSP90 antagonist, geldanamycin, inhibits proliferation, induces apoptosis and blocks migration of rhabdomyosarcoma cells in vitro and seeding into bone marrow in vivo. Anticancer Drugs 2007; 18: 1173-1181.
48. Georgakis GV, Li Y, Younes A. The heat shock protein 90 inhibitor 17-AAG induces cell cycle arrest and apoptosis in mantle cell lymphoma cell lines by depleting cyclin D1, Akt, Bid and activating caspase 9. Br J Haematol 2006; 135: 68-71.
49. Lyman SK, Crawley SC, Gong R, Adamkewicz JI, McGrath G, Chew JY et al. High-content, high-throughput analysis of cell cycle perturbations induced by the HSP90 inhibitor XL888. PLoS One 2011; 6: e17692.
50. Fu W, Ma Q, Chen L, Li P, Zhang M, Ramamoorthy S et al. MDM2 acts downstream of p53 as an E3 ligase to promote FOXO ubiquitination and degradation. J Biol Chem 2009; 284: 13987-14000.